Over the past decade, an expanding body of epidemiological and clinical trial data has been collated, culminating in the development of guidelines designed to help physicians make decisions about intervention and the intensity of treatment, based on objective assessments of the overall level of risk for cardiovascular disease. However, guidelines are not prescriptive and allow physicians leeway in interpretation. Thus, it is of clinical interest to explore some of the issues that may influ-
Introduction
This paper summarises a round table panel discussion, which was part of an official symposium at the European Society of Hypertension 9th European Meeting on Hypertension held in Milan on [11] [12] [13] [14] [15] June 1999. The aim of the round table was to explore whether practising physicians understand the concepts of 'absolute' and 'relative' cardiovascular risk and also to discuss the utility of such measures in clinical practice. The round table posed questions to an audience that represented a cross-section of specialists (almost 50% of the group) as well as primary care physicians and academic research workers.
Over the past decade, an expanding body of epidemiological and clinical trial data has been collated and assessed, culminating in the development of guidelines designed to help physicians make decisions about (i) intervention and (ii) the intensity of treatment, based on objective assessments of the overall level of risk for cardiovascular disease. Recent guidelines have been produced and updated in the USA by the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, 1 by the World Health Organisation in collaboration with the International Society of Hypertension, 2 by the Joint Task Force of European and other Societies on Coronary Prevention, and by the British Hypertension Society. 4 However, guidelines are not prescriptive and allow individual physicians leeway in interpretation. Thus, it is of interest to explore some of the issues that may influence the use of these guidelines in clinical practice. This was an interactive session in which the audience was invited to express views on practical clinical issues and these were commented upon by the panel of four experts. Two patient case histories were presented and used as the bases for discussion. A third is included in this paper.
Case history 1: the young hypertensive patient
Sarah is 28 and is married with a 2-year-old son. She works 3 days a week as a secretary, as well as looking after her family. Recently, she visited her local primary care physician for family planning advice, hoping to be prescribed an oral contraceptive. She complains of feeling constantly tired and has frequent headaches. A general health check revealed that Sarah is a non-smoker; she drinks approximately 4 -5 units of alcohol per week. Her weight is within the normal range for someone of her age and height. Blood pressure is elevated (systolic blood pressure (SBP): 156 mm Hg; diastolic blood pressure (DBP): 102 mm Hg). She also has an elevated serum cholesterol of 6.4 mmol/L (239 mg/dl) and high-density lipoprotein (HDL) cholesterol of 1.22 mmol/L (46 mg/dl) ( Table 1) . Sarah has had no significant previous illness and has no family history of cardiovascular disease; however, her grandfather died of a stroke at the age of 66 years. 
Discussion
Just over one-third (35%) of the audience considered that this young person with mild-to-moderate hypertension was a candidate for antihypertensive treatment. Treatment for hyperlipidaemia was advocated by 5% of the audience, while a further 30% thought that treatment was indicated for both the hypertension and hyperlipidaemia. The remaining 30% of the audience did not think that treatment was appropriate for either risk factor. The consensus from the expert panel was that, after exclusion of secondary causes of hypertension and end-organ damage, a period of observation was appropriate to establish the sustained blood pressure level that should be used to estimate cardiovascular risk. When asked to assess 10-year absolute cardiovascular risk (ie the percentage of women of the same age and risk profile, who will have a cardiovascular event over the next 10 years), approximately half of the audience (48%) thought that the risk was 1-10%, while a further 31% estimated that the absolute risk was even lower (less than 1%). In fact, the absolute risk of a cardiovascular event calculated from the Framingham equation was 0.4% for this young woman. Commenting on this, the expert panel noted that the long-term prognosis (beyond 10 years) could not be evaluated accurately using the Framingham equation and that the long-term consequence of risk factors in the young was not known. However, this young woman has a four-times greater risk of developing cardiovascular disease (0.4%) than an 'average' individual of the same age and sex within the population (0.1%); the average values for blood pressure and lipids in a female Caucasian of 28 years are given in Table 2 . 5 Most of the audience (69%) overestimated absolute risk, but the majority (76%) also underestimated the relative risk. (Table 2) , 5 the average absolute cardiovascular risk for a 60-year-old female in the population is estimated to be 11.5%. Thus, the relative risk for this patient projected to age 60 was only 1.5 times greater than the average values for women of age 60 within the general population. Although fewer members of the audience (55%) overestimated the absolute cardiovascular risk in this female projected to age 60, 77% of the audience overestimated the relative risk of this patient compared with an average person of the same age and sex within the population.
The reason for the decrease in relative risk for this individual is that the levels of blood pressure and cholesterol in the population increase with age, and there is a clustering of risk factors in the elderly 5 with an increase in the absolute risk of cardiovascuApplying evidence-based medicine to current practice GT McInnes et al S19 lar disease. However, while there are no long-term follow-up data available, it is likely that the risk factors found in this young patient will increase in severity over time and, therefore, a projection of risk based on risk factors at age 28 years is likely to be an underestimate of absolute risk at age 60. Until robust cohort data have been collected for two or three decades it will not be possible to refine the projection of risk factors further.
Prolonged hypertension can lead to cardiovascular complications, coronary heart disease (CHD), stroke, and renal damage.
6-8 However, since treatment of mild hypertension has been shown to prevent the development of more severe hypertension, 9 an important point for a clinician to consider is whether it is worth implementing early treatment in order to prevent progression.
The European Taskforce Guidelines 3 suggest that risk projection to age 60 may be useful in determining whether to intervene in the young. 3 Therefore, our young patient would be considered as a medium-risk patient who should be advised on lifestyle modifications, with drug intervention considered after 3-6 months if lifestyle modifications were unsuccessful (Table 3) . However, because this young patient's total cholesterol is у190 mg/dl (у5.0 mmol/L), the current guidelines recommend that she should be considered as a candidate for both lifestyle advice and drug therapy. Fifty percent of the audience considered that the projection of risk in the young to 60 years was a useful way of calculating risk.
Thus, while guidelines provide an easy access to evidence-based medicine there are difficulties in application and, for some patients, management decisions are not clear-cut. This is an important consideration when guidelines are used in everyday clinical practice.
For a young female with essential hypertension, such as Sarah, the consensus was that lifestyle interventions should be the initial approach, but if unsuccessful, antihypertensive and lipid-lowering therapy should be initiated.
The question of whether this patient should be given oral contraceptives remains to be addressed. A majority of the audience (55%) was in favour of prescribing oral contraceptives while 45% were not. This reflects a diversity of opinion on the safety of oral contraceptives in hypertension. Current evidence from limited trial data indicates that com- 
The audience was asked to assess the absolute cardiovascular risk for this patient. One-third (34%) of the audience thought that the absolute cardiovascular event risk over the next 10 years was greater than 30% for this patient, while the remaining participants were divided almost equally between a cardiovascular risk value of between 21 and 30% or р20%. Using the Framingham equation, the risk of CHD over the next 10 years was calculated as 16.7% Approximately 30% of clinicians thought that this individual was in a very high-risk category (Ͼ30%), rather than a high-risk group (21-30%). Physicians are notoriously poor at accurately predicting absolute cardiovascular risk. 4 However, one factor that may distort the clinical impression for this individual is that risk was calculated for a non-smoker, yet a history of 18 years' smoking that had only ceased 1 year ago would, in reality, make this individual more likely to have the risk profile of a smoker. 13, 14 Evaluation of risk for this patient as a smoker increases the absolute risk of CHD to 24.3% and that of stroke to 3.1%, giving a total cardiovascular risk of 27.4%. Multiplied by a factor of 1.5 for family history gives a total cardiovascular risk of 41.1%, making clinicians' estimations more accurate. When asked to estimate the absolute risk of cardiovascular disease if the patient had continued to smoke, almost half (49%) of physicians placed this patient in the very high-risk category (ie Ͼ40%). The expert panel considered that although no clinical trial data exist, observational data would suggest that a period of 5 years without cigarettes should elapse before somebody is classified as a non-smoker.
Compared with his peer group, this diabetic patient (with a recent history of smoking) has a 3.7 times greater risk of having a cardiovascular event over 10 years than an average male of 45 years; 50% of the audience accurately assessed this relative increase in risk. This case history clearly demonstrates the deleterious effects of cigarette smoking, which significantly increases both the absolute risk and relative risk of cardiovascular disease.
The majority of the audience (53%) considered that this high-risk patient was a candidate for drug treatment intervention for both hypertension and hyperlipidaemia; while 27% would treat only hypertension, 5% would treat only hyperlipidaemia. Surprisingly, 16% of the audience did not consider that a primary prevention with drug treatment was appropriate for this patient.
According to recent guidelines, 2 advice on lifestyle modifications and drug treatment for hypertension and hyperlipidaemia are clearly warranted for this high-risk patient. Of concern was the number of physicians who would not treat hyperlipidaemia in this patient. The value for total cholesterol was not especially high, but the total cholesterol:HDL ratio (200:30 mg/dl) was nearly 7. Data from the Framingham study have shown that the ratio of total cholesterol to HDL cholesterol provides a good estimate of the joint effect of these lipoprotein fractions and, at any blood pressure level, cardiovascular risk is markedly increased by an increased cholesterol:HDL ratio. 15 The consensus from the expert panel was that this patient is also a prime target for lifestyle modification. If the patient could reduce his body weight and decrease his alcohol consumption then his blood pressure and plasma lipids should also decrease. While abundant evidence for the benefits of, for example, diets low in saturated fatty acids and high in polyunsaturated fatty acids has been highlighted in both primary and secondary prevention studies, [16] [17] [18] [19] [20] [21] [22] considerable scepticism was expressed about the ability of any doctor to persuade such an individual to persist with rigorous lifestyle modifications.
Diabetes has a marked influence on risk, increasing risk of CHD, cardiovascular disease and total mortality. CHD is the most common complication for diabetes mellitus. Cardiovascular complications are the underlying cause of death in 57% of diabetic patients, with about 55% of deaths in diabetics due to ischaemic or other heart disease. 23 There is significant independent contribution of diabetes to CHD incidence but the effect is most pronounced in those with co-existent risk factors. 15 The UK Prospective Diabetes Study (UKPDS) 24 demonstrated that rigorous blood pressure control (mean 144/82 mm Hg) is an important factor in reducing the risk of diabetes-related death, stroke, heart failure and microvascular complications related to diabetes. For Surjit, adequate blood pressure control will be important to prevent complications from type II diabetes.
From a range of values between Ͻ120/80 mm Hg and Ͻ140/95 mm Hg, 34% of the audience selected a blood pressure of Ͻ130/80 mm Hg as the most appropriate target blood pressure for this individual, 22.5% selected Ͻ135/80 mm Hg and 21% considered Ͻ135/85 mm Hg to be most appropriate. Therefore, the consensus amongst physicians was that the target DBP should be Ͻ80 mm Hg; this is consistent with the findings from the Hypertension Optimal Treatment (HOT) trial, 25 which found a 51% lower rate of major cardiovascular events in the target group: р80 mm Hg compared with that in the target group (р90 mm Hg).
Fifty-four percent of physicians indicated that they would prescribe antiplatelet therapy (with lowdose aspirin) in this patient. In the HOT study, 25 patients who were randomised to aspirin showed a reduction in major cardiovascular events and myocardial infarction, but low-dose aspirin did not reduce stroke, overall cardiovascular mortality or total mortality. Furthermore, treatment with aspirin was associated with a high rate of non-fatal major and minor bleeding complications. Thus, the overall benefits are modest and only patients at high risk of vascular events are likely to obtain net gain. Whether Surjit qualifies for antiplatelet therapy remains contentious.
Case history 3: end-organ damage
John is a 45-year-old freelance computer programmer, running his business from home. He works long, irregular hours and drives many hundreds of kilometres every week to see his clients. Despite a history of high blood pressure, John admits to smoking at least 10 cigarettes per day. However, he has been encouraged to take up some regular light exer-cise and John now tries to fit in at least 20-30 min of swimming three times each week. His efforts have paid off. He has lost 6 kg but he remains overweight. John is symptom-free except for occasional heartburn. He has no family history of cardiovascular disease. The laboratory results reveal no evidence of renal damage or diabetes. John has a total serum cholesterol of 6.6 mmol/L (250 mg/dl) and an HDLcholesterol reading of 1.0 mmol/L (40 mg/dl) ( Table  5 ). John has been prescribed a thiazide diuretic. A follow-up visit with his physician reveals an average blood pressure reading of 142/93 mm Hg. His ECG suggests left ventricular hypertrophy and evidence of an old myocardial infarction. A subsequent ECG confirms left ventricular hypertrophy and indicates left ventricular dysfunction.
Discussion
John is an example of a relatively young patient with evidence of left ventricular hypertrophy and an old myocardial infarction. He continues to have slightly raised blood pressure following treatment with a low-dose diuretic. The absolute risk of a cardiovascular event within the next 10 years is high. Use of the Framingham equation is inappropriate in an individual who has suffered from a myocardial infarction. However, even ignoring the pre-existing cardiac damage, the calculated risk of CHD over the next 10 years is 38% and the risk of stroke is 2.5%, giving a total cardiovascular risk of 41%. Compared with his male peers of between 45 and 59 years of age, 26 John has a 3.5 times greater risk of CHD. In keeping with his very high-risk profile, he needs continued support and encouragement to maintain a healthier lifestyle and additional treatment options must be considered to better manage his hypertension. 2 In addition, lipid-lowering therapy is mandatory as part of a secondary prevention strategy. 2 
Conclusion
Current guidelines illustrate the benefits of stratifying patients according to cardiovascular risk and 
